Braun D, Yang J, Griffin M, Parmigiani G, Hughes KS. A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. Journal of genetic counseling. 2018 :1–13.
Pencina MJ, Chipman J, Steyerberg EW, Braun D, Fine JP, D'Agostino RB. Authors' response to comments. Statistics in medicine. 2017;36 (28) :4511–4513.
Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK, Griffin M, Hughes KS. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Research and Treatment. 2017 :1–22.
Braun D, Gorfine M, Katki HA, Ziogas A, Parmigiani G. Nonparametric Adjustment for Measurement Error in Time to Event Data: Application to Risk Prediction Models. Journal of the American Statistical Association. 2017;(just-accepted).
Braun D, Gorfine M, Parmigiani G, Arvold ND, Dominici F, Zigler C. Propensity scores with misclassified treatment assignment: a likelihood-based adjustment. Biostatistics. 2017;18 (4) :695–710.
Chipman J, Braun D. Simpson's paradox in the integrated discrimination improvement. Statistics in medicine. 2017;36 (28) :4468–4481.
Horvitz-Lennon M, Braun D, Normand S-L. Challenges in the Use of Administrative Data for Heart Failure Services Research. Journal of cardiac failure. 2016;22 (1) :61–63.
Braun D, Gorfine M, Parmigiani G. Misreported family histories and underestimation of risk. Journal of Clinical Oncology. 2014;32 (32) :3682–3683.
Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Annals of oncology. 2011;22 (9) :1981–1987.
Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of oncology. 2011;22 (10) :2216–2226.